Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) Short Interest Up 30.2% in March

Posted by Casey Walker on Apr 1st, 2025

Global X Genomics & Biotechnology ETF (NASDAQ:GNOM – Get Free Report) saw a large growth in short interest in the month of March. As of March 15th, there was short interest totalling 16,400 shares, a growth of 30.2% from the February 28th total of 12,600 shares. Based on an average daily volume of 77,600 shares, the days-to-cover ratio is presently 0.2 days. Currently, 0.3% of the company’s shares are short sold.

Institutional Trading of Global X Genomics & Biotechnology ETF

Several hedge funds have recently modified their holdings of GNOM. Comprehensive Money Management Services LLC bought a new position in Global X Genomics & Biotechnology ETF during the fourth quarter worth $178,000. Armis Advisers LLC bought a new stake in Global X Genomics & Biotechnology ETF in the 4th quarter valued at about $432,000. Two Sigma Investments LP increased its position in Global X Genomics & Biotechnology ETF by 74.5% in the 4th quarter. Two Sigma Investments LP now owns 85,500 shares of the company’s stock valued at $830,000 after buying an additional 36,500 shares in the last quarter. Strive Asset Management LLC bought a new position in Global X Genomics & Biotechnology ETF in the fourth quarter worth approximately $409,000. Finally, Citadel Advisors LLC acquired a new stake in Global X Genomics & Biotechnology ETF in the fourth quarter valued at approximately $148,000. Institutional investors own 56.95% of the company’s stock.

Global X Genomics & Biotechnology ETF Trading Down 1.4 %

NASDAQ GNOM traded down $0.11 during trading hours on Tuesday, hitting $7.84. 53,761 shares of the company’s stock were exchanged, compared to its average volume of 61,847. Global X Genomics & Biotechnology ETF has a 1-year low of $7.84 and a 1-year high of $11.88. The stock has a 50-day simple moving average of $9.41 and a 200 day simple moving average of $10.12. The firm has a market cap of $54.64 million, a price-to-earnings ratio of -3.35 and a beta of 1.03.

About Global X Genomics & Biotechnology ETF

(Get Free Report)

Complete Genomics, Inc is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research.